🇺🇸 FDA
Pipeline program

Balugrastim

NEUGR-002

Phase 3 mab completed

Quick answer

Balugrastim for Chemotherapy-induced Neutropenia is a Phase 3 program (mab) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
Chemotherapy-induced Neutropenia
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials